Organisation paid for research Program year 2025 Source: CMS Open Payments

Weitzner Yonker Kaine

Neither a doctor nor a teaching hospital

Research payments

$342,417

16 payments

Through program year 2025, Weitzner Yonker Kaine is reported as receiving $342,417 in research payments, across 16 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$82,139	6
2024	Research	$204,050	6
2023	Research	$51,702	2
2022	Research	$3,101	1
2020	Research	$1,424	1

Breakdown

Who paid Research payments · program years 2020–2025

Novartis Pharmaceuticals Corporation $342,417 16 payments

Studies the money was for Research payments · program years 2020–2025

A Randomized, Double-Blind, Placebo Controlled, 3-Arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (Neptunus-2) $171,615 4 payments
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome $67,889 2 payments
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 MG Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (Gca) $63,388 2 payments
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 MG Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien $15,169 1 payment
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis $10,500 2 payments
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis suppurativa $6,000 1 payment
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) $5,000 1 payment
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup $1,432 2 payments
A Phase III Randomized Double Blind Placebo Controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy Safety and Tolerability Up to 5 Years in Patients With $1,424 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.